[1]CurrentPatentAssignee:BAYERAG-EP1228063,2009,B1Locationinpatent:Page/Pagecolumn64
[2]CurrentPatentAssignee:BAYERAG-WO2007/118602,2007,A1Locationinpatent:Page/Pagecolumn90
[3]CurrentPatentAssignee:BAYERAG-US6689883,2004,B1Locationinpatent:Pagecolumn101-102
[1]CurrentPatentAssignee:BAYERAG-EP1228063,2009,B1Locationinpatent:Page/Pagecolumn45
[2]CurrentPatentAssignee:BAYERAG-WO2007/118602,2007,A1Locationinpatent:Page/Pagecolumn67;68
[3]CurrentPatentAssignee:BAYERAG-US6689883,2004,B1Locationinpatent:Pagecolumn60-61
[1]CurrentPatentAssignee:BAYERAG-WO2007/118602,2007,A1Locationinpatent:Page/Pagecolumn68;69;75;79
[2]CurrentPatentAssignee:BAYERAG-US6689883,2004,B1Locationinpatent:Pagecolumn61
[1]CurrentPatentAssignee:BAYERAG-EP1228063,2009,B1Locationinpatent:Page/Pagecolumn45-46
[2]CurrentPatentAssignee:BAYERAG-EP1228063,2009,B1Locationinpatent:Page/Pagecolumn50-51;54
[1]CurrentPatentAssignee:EDDINGPHARMCOLTD-CN104804008,2016,BLocationinpatent:Paragraph0029;0034;0035
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
Journal: Journal of medicinal chemistry 20121227
Title: The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?
Journal: Arzneimittel-Forschung 20120401
Title: Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20111101
Title: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Journal: Journal of the National Cancer Institute 20110504
Title: Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Journal: Current oncology reports 20110401
Title: Targeted therapies for metastatic esophagogastric cancer.
Journal: Current treatment options in oncology 20110301
Title: Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.
Journal: Investigational new drugs 20110201
Title: Common secondary causes of resistant hypertension and rational for treatment.
Journal: International journal of hypertension 20110101
Title: Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.
Journal: Cardiology research and practice 20110101
Title: Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.
Journal: Vascular cell 20110101
Title: Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Journal: European journal of medicinal chemistry 20101101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20100901
Title: A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
Journal: Journal of pharmacokinetics and pharmacodynamics 20100801
Title: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Journal: Journal of the National Cancer Institute 20100505
Title: Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100401
Title: Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901
Title: Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
Journal: British journal of cancer 20081104
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20081001
Title: Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080601
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20070601
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20070101
Title: Steeghs N, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008 Jun 1;14(11):3470-6.
Title: Langenberg MH, et al. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clin Cancer Res. 2010 Apr 1;16(7):2187-97.
Title: Steeghs N, et al. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Invest New Drugs. 2011 Feb;29(1):137-43.
Title: Sodani K, et al. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol. 2014 May 1;89(1):52-61.
